Previously, we reported the usage of anti-hTfR scFv fused viral peptide/HLA-A2 complex to redirect cytotoxic T cells of viral specificity to TfR-expressing K562 cells [4] and Tf conjugated polyplexes [5] to deliver therapeutic HIF-1α shRNA into various TfR-expressing tumor cell lines. Here, TFRC is linked to neoplasm.